Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States.

ABSTRACT:

Introduction

Eculizumab is a licensed treatment for several rare, complement-mediated diseases. Eculizumab use is associated with an approximately 2,000-fold increased meningococcal disease risk. In the United States, meningococcal vaccines are recommended for eculizumab recipients but there are no recommendations on use of long-term antibiotic prophylaxis. We describe characteristics of and meningococcal vaccine and antibiotic receipt in U.S. eculizumab recipients to inform meningococcal disease prevention strategies.

Methods

Persons in the IBM® MarketScan® Research Databases with ≥1 claim for eculizumab injection during 2007-2017 were included. Indication for eculizumab use, meningococcal vaccine receipt, and antibiotic receipt were assessed using International Classificat

SUBMITTER: Bozio CH 

PROVIDER: S-EPMC7660549 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature